Syndax Announces Multiple Data Presentations On Entinostat At Upcoming San Antonio Breast Cancer Symposium

WALTHAM, Mass., Dec. 3, 2015 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple cancer indications, announced today upcoming multiple presentations of data on entinostat at the 2015 San Antonio Breast Cancer Symposium (SABCS) taking place December 8-12 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

Thursday, December 10, 2015 - 7:30 AM, Poster Session 2: Treatment: Immunotherapy: Saranya Chumsri, M.D., Department of Hematology/Oncology at the Mayo Clinic will present Poster P2-11-10 entitled "Epigenetic immune modulation by entinostat in breast cancer: Correlative analysis of ENCORE 301 trial."

Thursday, December 10, 2015 - 7:30 AM, Poster Session 2: Tumor Cell and Molecular Biology: Epigenetics: Saranya Chumsri, M.D., Department of Hematology/Oncology at the Mayo Clinic will present Poster P2-04-02 entitled "Immunomodulatory effects of entinostat on PD-L1 and MHC class I and II in different subtypes of breast cancer."

Thursday, December 10, 2015 - 5:00 PM, in Session on Ongoing Clinical Trials: Ongoing Trials - Endocrine Therapies: Roisin Connolly, M.B., B.Ch., Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, will present Poster OT2-01-04, a clinical update on study "E2112: Randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group."

Friday, December 11, 2015 - 7:30 AM, Poster Session 4: Treatment: HER2-Targeted Therapy: Bora Lim, M.D., Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, will present Poster P4-14-22 entitled "A single-center, open-label phase 1b study of entinostat, and lapatinib alone, and in combination with trastuzumab in patients with HER2+ metastatic breast cancer after progression on trastuzumab."

Friday, December 11, 2015 - 5:00 PM, Poster Session 5: Tumor Cell and Molecular Biology: New Drugs and Mechanisms: Maki Tanioka, M.D., University of North Carolina at Chapel Hill, will present Poster P5-03-05 entitled "Genomic analysis and efficacy of entinostat in basal-like and HER2-overexpressing models."

Friday, December 11, 2015 - 5:00 PM, Poster Session 5: Tumor Cell and Molecular Biology: Novel/Emerging Therapeutic Targets: Angela M. Torres-Adorno, M.D., of the University of Texas Graduate School of Biomedical Sciences at Houston and the Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, will present Poster P5-04-02 entitled "The histone deacetylase inhibitor entinostat enhances the efficacy of the MEK inhibitor pimasertib against aggressive types of breast cancer through Noxa-mediated myeloid cell leukemia 1 degradation."

About Syndax Pharmaceuticals, Inc.
Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma and triple-negative breast cancer (TNBC). Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body's immune response to tumors. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma and with Genentech, Inc. for TNBC, as well as in a Phase 3 clinical trial with ECOG-ACRIN for advanced hormone receptor positive breast cancer, an indication for which entinostat was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration. For more information on Syndax please visit www.syndax.com.

Syndax's Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements contained in this press include, without limitation, statements regarding the timing of presenters' abstracts. Words such as "may," "believe," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance and involve a number of unknown risks, assumptions, uncertainties and factors that are beyond Syndax's control. All forward-looking statements are as of the date of this press release. Actual results may differ materially from these forward-looking statements. Except as required by law, Syndax expressly disclaims any responsibility to update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise.

Investor and Media Contacts

Karen L. Bergman
BCC Partners
(650) 575-1509
[email protected]

Jen LaVin
BCC Partners
(617) 718-0276
[email protected]

SOURCE Syndax Pharmaceuticals, Inc.

Related Links

http://www.syndax.com